For illustrative purposes. Populations of cancerous cells differ from patient to patient.
Although DLBCL can occur at any age, its occurrence increases with age. Most people are first diagnosed between the ages of 65 and 74.
DLBCL can affect both men and women, although it is slightly more common in men.
The cause of DLBCL is unknown.
Relapse happens when the cancer or the signs and symptoms of the cancer return after responding to previous treatment.
Refractory refers to a disease that has not responded to previous treatment.
Relapsed or refractory diffuse large B-cell lymphoma is often referred to as R/R DLBCL.
POLIVY® is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have progressed after at least 2 prior therapies.
The conditional approval of POLIVY is based on a type of response rate. There are ongoing studies to establish how well the drug works.
Everyone reacts differently to POLIVY therapy, so it’s important to know what the side effects are. Some people who have been treated with POLIVY have experienced serious to fatal side effects. Your doctor may stop or adjust your treatment if any serious side effects occur. Be sure to contact your healthcare team if there are any signs of these side effects.
Side effects seen most often
The most common side effects during treatment were
POLIVY may not be for everyone. Talk to your doctor if you are
These may not be all the side effects. Talk to your healthcare provider for more information about the benefits and risks of POLIVY treatment.
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see the full Prescribing Information for additional Important Safety Information.
The information contained in this section of the site is intended for US healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.